iRadimed Corporation (NASDAQ:IRMD) Stock Has Consensus Target Price of $120.00

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $120.00.

IRMD has been the subject of a number of research reports. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th. Finally, Needham & Company LLC initiated coverage on iRadimed in a report on Tuesday, September 22nd. They set a “hold” rating on the stock.

Insider Transactions at iRadimed

In other news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the transaction, the director owned 19,581 shares in the company, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 34.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On iRadimed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRMD. BlackRock Inc. acquired a new stake in iRadimed during the 2nd quarter worth approximately $92,485,000. Dimensional Fund Advisors LP raised its holdings in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after acquiring an additional 9,017 shares in the last quarter. Ranger Investment Management L.P. acquired a new stake in shares of iRadimed during the 2nd quarter worth $9,398,000. Bank of New York Mellon Corp bought a new position in shares of iRadimed in the second quarter worth $7,252,000. Finally, Sei Investments Co. grew its stake in iRadimed by 17.2% during the first quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider’s stock worth $7,153,000 after buying an additional 10,908 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Down 2.1%

Shares of NASDAQ IRMD opened at $85.82 on Friday. The stock has a market capitalization of $1.10 billion, a P/E ratio of 47.94 and a beta of 0.91. The stock’s 50 day moving average price is $86.02 and its two-hundred day moving average price is $90.10. iRadimed has a 52-week low of $75.75 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts anticipate that iRadimed will post 1.98 EPS for the current year.

iRadimed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is presently 44.69%.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.